Prevention of irinotecan (CPT-11)-induce
โ
Yuichiro Takeda; Kunihiko Kobayashi; Yoshiko Akiyama; Tomoyuki Soma; Satoko Hand
๐
Article
๐
2001
๐
John Wiley and Sons
๐
French
โ 92 KB
It has been reported that 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin (CPT-11) and its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), have absorption characteristics of weakly basic drugs, suggesting that alkalization of the intestinal lumen might reduce reabsorpt